ConductScience.org, home

Comparison · NCT00931723-c5f2c8b5

Lithium+Quetiapine XR vs Placebo+Quetiapine XR: Improvement of Overall Bipolar Illness

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Lithium+Quetiapine XR vs Placebo+Quetiapine XR: Improvement of Overall Bipolar Illness. Trial comparisons, record NCT00931723-c5f2c8b5. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00931723-c5f2c8b5

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.7750.7070.83wilson
Risk in group 20.710.6390.772wilson
Risk difference, group 1 minus group 20.0643-0.02750.155newcombe hybrid score
Risk ratio, group 1 over group 21.090.9631.23log
Odds ratio, group 1 over group 21.40.8652.27log
Number needed to treat, for one more participant with the outcome on Lithium+Quetiapine XR than on Placebo+Quetiapine XR15.5from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Lithium+Quetiapine XRLithium 600 to 1800 mg/day+quetiapine XR 400 to 800 mg/day134173OG000
Group 2Placebo+Quetiapine XRPlacebo+quetiapine XR 400 to 800 mg/day125176OG001

Outcome

Type
SECONDARY
Title
Improvement of Overall Bipolar Illness
Description
The number of patients with a CGI-BP-C of Much or Very much improved in overall bipolar illness assessment at Day 43 was calculated.~The CGI-BP-C scale rates how much the patient's illness has improved or worsened compared to the phase immediately preceding treatment and is scored on a scale from 1 to 8 (1=very much improved to 7=very much worse; 8=not applicable). A missing score will be used when a scale scored as 8 (not applicable). CGI-BP-C scores \>4 indicate worsening, while scores \<4 indicate improvement.
Time frame
Day 43.
Population
173/176 is modified intent to treat analysis set. The reason why is different from 173/183 is that there is 7 patients excluded from the analysis (1 patient who did not take study drug and 6 patients who did not have post treatment YMRS scores).

Source ClinicalTrials.gov

Trial

Title
Adult Bipolar Mania
NCT number
NCT00931723
Phases
PHASE4
Conditions
Acute Mania
Interventions
Quetiapine fumarate XR, Lithium, Placebo
Lead sponsor
AstraZeneca
Results first posted
2012-04-19

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT00931723-c5f2c8b5